Towards preserving the immunogenicity of protein antigens carried by nanoparticles while avoiding the cold chain

International Journal of Pharmaceutics

Volumn 393, Issue 1-2, 2010, Pages 198-203

  Sloat, Brian R ^a,b   Sandoval, Michael A ^b   Cui, Zhengrong ^b  

^a OREGON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Antibody response; Lyophilization; Vaccine storage

Indexed keywords

ANTHRAX VACCINE; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BOVINE SERUM ALBUMIN; MANNITOL; NANOPARTICLE; POVIDONE; ACYLGLYCEROL; ANTHRAX TOXIN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; DRUG CARRIER; EXCIPIENT; GLYCEROL STEARATE; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ARTICLE; BACILLUS ANTHRACIS; CONTROLLED STUDY; CRYOPRESERVATION; DRUG EFFICACY; DRUG QUALITY; DRUG STORAGE; FEASIBILITY STUDY; FEMALE; FREEZE DRYING; FREEZING; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; COLD; DRUG FORMULATION; DRUG STABILITY; EVALUATION; IMMUNOLOGY; METHODOLOGY; PHARMACEUTICS; PROTEIN CONFORMATION; PROTEIN STABILITY; TIME;

ANIMALS; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CHEMISTRY, PHARMACEUTICAL; COLD TEMPERATURE; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; FEASIBILITY STUDIES; FEMALE; FREEZE DRYING; GLYCERIDES; LECITHINS; MANNITOL; MICE; MICE, INBRED BALB C; NANOPARTICLES; POVIDONE; PROTEIN CONFORMATION; PROTEIN STABILITY; SERUM ALBUMIN, BOVINE; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 77953361173     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.04.003     Document Type: Article

References (21)

1. Amorij J.P., Huckriede A., Wilschut J., Frijlink H.W., Hinrichs W.L. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm. Res. 2008, 25:1256-1273.
2. Carpenter J.F., Pikal M.J., Chang B.S., Randolph T.W. Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res. 1997, 14:969-975.
3. Chang B.S., Beauvais R.M., Dong A., Carpenter J.F. Physical factors affecting the storage stability of freeze-dried interleukin-1 receptor antagonist: glass transition and protein conformation. Arch. Biochem. Biophys. 1996, 331:249-258.
4. Chen D., Kristensen D. Opportunities and challenges of developing thermostable vaccines. Expert Rev. Vaccines 2009, 8:547-557.
5. Clark T.G., Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. Dev. Biol. 2005, 121:153-163.
6. Connors K.A., Amidon G.L., Stella V.J. Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists 1985, Wiley, John & Sons, Inc., New York. 2nd ed.
7. Crowe J.H., Carpenter J.F., Crowe L.M. The role of vitrification in anhydrobiosis. Annu. Rev. Physiol. 1998, 60:73-103.
8. Cui Z., Lockman P.R., Atwood C.S., Hsu C.H., Gupte A., Allen D.D., Mumper R.J. Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm. 2005, 59:263-272.
9. Cui Z., Qiu F., Sloat B.R. Lecithin-based cationic nanoparticles as a potential DNA delivery system. Int. J. Pharm. 2006, 313:206-213.
10. Kim A.I., Akers M.J., Nail S.L. The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate, and a noncrystallizing cosolute. J. Pharm. Sci. 1998, 87:931-935.
11. La-Chapelle J. Thesaurismose cutanee par polyvinylpyrrolidone. Dermatologica 1966, 132:476-489.
12. Perrie Y., Mohammed A.R., Kirby D.J., McNeil S.E., Bramwell V.W. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 2008, 364:272-280.
13. Roy M.L., Pikal M.J., Rickard E.C., Maloney A.M. The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: a test of the WLF glass transition theory. Dev. Biol. Stand. 1992, 74:323-340.
14. Shackell L. An improved method of desiccation, with some applications to biological problems. Am. J. Physiol. 1909, 24:325-340.
15. Singh M., Chakrapani A., O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev. Vaccines 2007, 6:797-808.
16. Sloat B.R., Cui Z. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine 2006, 24:6405-6413.
17. Sloat B.R., Sandoval M.A., Hau A.M., He Y., Cui Z. Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. J. Control. Release 2010, 141:93-100.
18. Wade A., Weller P.J. Handbook of Pharmaceutical Excipients 1994, The Pharmaceutical Press, London. 2nd ed.
19. Wang W. Lyophilization and development of solid protein pharmaceuticals. Intl. J. Pharm. 2000, 203:1-60.
20. Yanasarn N., Sloat B.R., Cui Z. Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel. Intl. J. Pharm. 2009, 379:174-180.
21. Young J.A., Collier R.J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 2007, 76:243-265.